blinatumomab

Blinatumomab is a first-in-class bispecific T-cell engager (BiTE) antibody that targets CD19 on B cells and CD3 on T cells. It is designed to direct the body's cytotoxic T cells to recognize and eliminate malignant B cells by physically linking them, thereby activating the immune response against cancerous B lymphoblasts. Blinatumomab is primarily indicated for the treatment of relapsed or refractory precursor B-cell acute lymphoblastic leukemia (ALL) in both adults and children, including those with minimal residual disease (MRD). The drug was originally developed by Micromet Inc., later acquired by Amgen, which commercializes it globally. In China, BeiGene holds commercialization rights. Blinatumomab received FDA approval in 2014 and has since been approved in multiple regions for various ALL indications[1][2][4][5][6].

Brand names

BLINCYTO倍利妥

Other names

贝林妥欧单抗